Literature DB >> 12811639

Early and persistent alterations in prefrontal cortex MAO A and B in Alzheimer's disease.

B P Kennedy1, M G Ziegler, M Alford, L A Hansen, L J Thal, E Masliah.   

Abstract

Both monoamine oxidase (MAO) A and MAO B in the brain have been implicated in the etiology of Alzheimer's disease. MAO B is elevated in plaque-associated glia in Alzheimer brain. Elevations in MAO A in Alzheimer neurons have been linked to increases in neurotoxic metabolites and neuron loss. We investigated the relationship between cognitive function in Alzheimer patients and post-mortem prefrontal cortex MAO A and B activities. Prefrontal cortex tissue from 92 Alzheimer patients and 74 neurologically normal subjects was obtained at autopsy and analyzed for activities of MAO A and B by radioenzymatic methods. Mini Mental Status Exam was performed on Alzheimer patients within 1 year of death. Alzheimer brains were analyzed for Braak stage, tangles, plaques and choline acetyltransferase activity. Prefrontal cortex MAO B activity was significantly increased by 16% in Alzheimer patients versus normals, whereas MAO A activity was significantly decreased by 17% in these same patients. Neither MAO A nor MAO B activities correlated with cognitive function (MMSE score), choline acetyltransferase activity, plaques, neurofibrillary tangles, Braak stage, or age of disease onset in the Alzheimer patients. With increasing Alzheimer duration or increasing Braak stage, MMSE scores and choline acetyltransferase activity declined, but levels of MAO A and B in prefrontal cortex were unchanged. Patients in the upper quintile for MAO A or B activity did not differ significantly from those in the lowest quintile with respect to MMSE scores or age of Alzheimer disease onset. We conclude that the changes in MAO A and B in the prefrontal cortex occur very early in Alzheimer's disease and remain relatively constant as the disease progresses.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12811639     DOI: 10.1007/s00702-003-0828-6

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  18 in total

1.  Progress in the development of new drugs in Alzheimer's disease.

Authors:  Antoine Piau; F Nourhashémi; C Hein; C Caillaud; B Vellas
Journal:  J Nutr Health Aging       Date:  2011-01       Impact factor: 4.075

2.  Aspartic acid substitutions in monoamine oxidase-A reveal both catalytic-dependent and -independent influences on cell viability and proliferation.

Authors:  Zelan Wei; Tamara Satram-Maharaj; Bradley Chaharyn; Kelly Kuski; Paul R Pennington; Xia Cao; Jennifer Chlan; Darrell D Mousseau
Journal:  J Neural Transm (Vienna)       Date:  2012-03-03       Impact factor: 3.575

3.  Alzheimer disease-related presenilin-1 variants exert distinct effects on monoamine oxidase-A activity in vitro.

Authors:  Paul R Pennington; Zelan Wei; Lewei Rui; Jennifer A Doig; Brett Graham; Kelly Kuski; Geraldine G Gabriel; Darrell D Mousseau
Journal:  J Neural Transm (Vienna)       Date:  2011-03-04       Impact factor: 3.575

Review 4.  Perspectives on MAO-B in aging and neurological disease: where do we go from here?

Authors:  M Jyothi Kumar; Julie K Andersen
Journal:  Mol Neurobiol       Date:  2004-08       Impact factor: 5.590

5.  Characterization of detergent purified recombinant rat liver monoamine oxidase B expressed in Pichia pastoris.

Authors:  Anup K Upadhyay; Dale E Edmondson
Journal:  Protein Expr Purif       Date:  2008-03-10       Impact factor: 1.650

6.  Monoamine Oxidase Inhibitors: From Classic to New Clinical Approaches.

Authors:  Pablo Duarte; Antonio Cuadrado; Rafael León
Journal:  Handb Exp Pharmacol       Date:  2021

Review 7.  Role of Monoamine Oxidase Activity in Alzheimer's Disease: An Insight into the Therapeutic Potential of Inhibitors.

Authors:  Tapan Behl; Dapinder Kaur; Aayush Sehgal; Sukhbir Singh; Neelam Sharma; Gokhan Zengin; Felicia Liana Andronie-Cioara; Mirela Marioara Toma; Simona Bungau; Adrian Gheorghe Bumbu
Journal:  Molecules       Date:  2021-06-18       Impact factor: 4.411

Review 8.  Key Targets for Multi-Target Ligands Designed to Combat Neurodegeneration.

Authors:  Rona R Ramsay; Magdalena Majekova; Milagros Medina; Massimo Valoti
Journal:  Front Neurosci       Date:  2016-08-22       Impact factor: 4.677

9.  Positron emission tomography measurement of brain MAO-B inhibition in patients with Alzheimer's disease and elderly controls after oral administration of sembragiline.

Authors:  Stefan Sturm; Anton Forsberg; Stephane Nave; Per Stenkrona; Nicholas Seneca; Andrea Varrone; Robert A Comley; Patrik Fazio; Candice Jamois; Ryuji Nakao; Zbigniew Ejduk; Nabil Al-Tawil; Ulrika Akenine; Christer Halldin; Niels Andreasen; Benedicte Ricci
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-09-16       Impact factor: 9.236

10.  Calcium-sensitive regulation of monoamine oxidase-A contributes to the production of peroxyradicals in hippocampal cultures: implications for Alzheimer disease-related pathology.

Authors:  Xia Cao; Zelan Wei; Geraldine G Gabriel; XinMin Li; Darrell D Mousseau
Journal:  BMC Neurosci       Date:  2007-09-16       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.